These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20452541)

  • 21. A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes).
    Sorice GP; Folli F
    Med Hypotheses; 2009 Oct; 73(4):614-8. PubMed ID: 19577852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.
    Habashi JP; Doyle JJ; Holm TM; Aziz H; Schoenhoff F; Bedja D; Chen Y; Modiri AN; Judge DP; Dietz HC
    Science; 2011 Apr; 332(6027):361-5. PubMed ID: 21493863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II type 1 receptor-dependent nuclear factor-kappaB activation-mediated proinflammatory actions in a rat model of obstructive acute pancreatitis.
    Chan YC; Leung PS
    J Pharmacol Exp Ther; 2007 Oct; 323(1):10-8. PubMed ID: 17616560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to explain the differences between renin angiotensin system modulators.
    Levy BI
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.
    Verbrugghe P; Verhoeven J; Clijsters M; Vervoort D; Schepens J; Meuris B; Herijgers P
    J Cardiovasc Pharmacol; 2018 Apr; 71(4):215-222. PubMed ID: 29300219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
    Bayorh MA; Ganafa AA; Eatman D; Walton M; Feuerstein GZ
    Am J Hypertens; 2005 Nov; 18(11):1496-502. PubMed ID: 16280288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
    Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH
    Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical treatment of Marfan syndrome: a time for change.
    Williams A; Davies S; Stuart AG; Wilson DG; Fraser AG
    Heart; 2008 Apr; 94(4):414-21. PubMed ID: 18347371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?
    Hollenberg NK
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S7-13. PubMed ID: 17401314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.
    Garg S; Narula J; Marelli C; Cesario D
    Am J Cardiol; 2006 Mar; 97(6):921-5. PubMed ID: 16516603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats.
    Ito N; Ohishi M; Yamamoto K; Tatara Y; Shiota A; Hayashi N; Komai N; Yanagitani Y; Rakugi H; Ogihara T
    Am J Hypertens; 2007 Jul; 20(7):792-9. PubMed ID: 17586415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is losartan the drug for all seasons?
    Ramirez F; Rifkin DB
    Curr Opin Pharmacol; 2012 Apr; 12(2):223-4. PubMed ID: 22445547
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis.
    Price A; Lockhart JC; Ferrell WR; Gsell W; McLean S; Sturrock RD
    Arthritis Rheum; 2007 Feb; 56(2):441-7. PubMed ID: 17265479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renin inhibition: what are the clinical perspectives?
    Hollenberg NK
    Semin Nephrol; 2007 Sep; 27(5):511-8. PubMed ID: 17868787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transforming growth factor beta1 mediates apoptotic activity of angiotensin II type I receptor blocker on prostate epithelium in vitro.
    Zhao Y; Peng J; Zheng L; Yu W; Jin J
    Prostate; 2010 Jun; 70(8):899-905. PubMed ID: 20135646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A small molecule for a large disease.
    Pyeritz RE
    N Engl J Med; 2008 Jun; 358(26):2829-31. PubMed ID: 18579819
    [No Abstract]   [Full Text] [Related]  

  • 38. Different protective actions of losartan and tempol on the renal inflammatory response to acute sodium overload.
    Rosón MI; Della Penna SL; Cao G; Gorzalczany S; Pandolfo M; Toblli JE; Fernández BE
    J Cell Physiol; 2010 Jul; 224(1):41-8. PubMed ID: 20232302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of suppressing the renin-angiotensin system on atrial fibrillation.
    Kalus JS; Coleman CI; White CM
    J Clin Pharmacol; 2006 Jan; 46(1):21-8. PubMed ID: 16397280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.